Demographics and Survival Outcomes of Burkitt Lymphoma in the US: A Hospital-Based Study from the National Cancer Database with Focus on Hispanics

BACKGROUND: Burkitt lymphoma (BL) is an aggressive B cell non-Hodgkin lymphoma primarily caused by MYC gene deregulation on chromosome 8 ( BloodPMID: 33171490). In the US, both sporadic and immunodeficiency-associated variants of BL are common, and their treatment and prognosis are generally similar ( BloodPMID: 15265787). BL is typically diagnosed at a median age of 30. However, the underrepresentation of Hispanics (HI) in previous studies has led to an incomplete and inaccurate representation of this population. ( J Clin OncolPMID: 9704731) To address this knowledge gap, a comprehensive nationwide study is underway to investigate the demographic, clinical, and survival outcomes of HI and non-Hispanic (NH) patients with BL. METHODS: Data from BL patients in the US (reported to NCDB between 2004 and 2019) were analyzed. Demographics, treatments, and overall survival (OS) were compared across ethnic groups. Kaplan-Meier and Cox regression analyses OS between HI and NH. Multivariate analysis and propensity score matching adjusted for age, stage, co-morbidity score, insurance status, facility type, and great circle distance. RESULTS: Among the 11,015 BL patients analyzed, 12% were HI and 84% were NH. Most were male (HI 76%, NH 74%) and diagnosed before age 65 (83% vs.72%). HI patients were younger (mean 47 years) than NH patients (mean 52 years) (p-value